Get the Stockscreener App
25.45
1.03%
0.26
After Hours:
25.43
-0.02
-0.08%
Alto Neuroscience Inc stock is traded at $25.45, with a volume of 292.60K.
It is up +1.03% in the last 24 hours and up +17.39% over the past month.
Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individual's neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-207, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.
See More
Previous Close:
$25.19
Open:
$25.91
24h Volume:
292.60K
Relative Volume:
1.02
Market Cap:
$892.09M
Revenue:
-
Net Income/Loss:
$-63.24M
P/E Ratio:
-11.34
EPS:
-2.2449
Net Cash Flow:
$-51.79M
1W Performance:
+4.00%
1M Performance:
+17.39%
6M Performance:
+125.42%
1Y Performance:
+982.98%
1-Day Range:
$24.80
$26.78
1-Week Range:
$23.28
$26.78
52-Week Range:
$2.12
$28.44
Alto Neuroscience Inc Stock (ANRO) Company Profile
Name
Alto Neuroscience Inc
Sector
Industry
Phone
773-255-5012
Address
650 CASTRO STREET, SUITE 450, MOUNTAIN VIEW
Compare ANRO vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANRO
Alto Neuroscience Inc
|
25.45 | 882.98M | 0 | -63.24M | -51.79M | -2.2449 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Alto Neuroscience Inc Stock (ANRO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-05-26 | Resumed | Chardan Capital Markets | Buy |
| Nov-17-25 | Initiated | BTIG Research | Buy |
| Sep-29-25 | Initiated | Chardan Capital Markets | Buy |
| Oct-23-24 | Downgrade | Rodman & Renshaw | Buy → Neutral |
| Oct-23-24 | Downgrade | Wedbush | Outperform → Neutral |
| Sep-03-24 | Initiated | Wedbush | Outperform |
| Feb-27-24 | Initiated | Jefferies | Buy |
| Feb-27-24 | Initiated | Robert W. Baird | Outperform |
| Feb-27-24 | Initiated | Stifel | Buy |
| Feb-27-24 | Initiated | TD Cowen | Outperform |
| Feb-27-24 | Initiated | William Blair | Outperform |
View All
Alto Neuroscience Inc Stock (ANRO) Latest News
Alto Neuroscience (ANRO) Price Target Increased by 81.11% to 19.09 - MSN
BofA Securities Initiates Alto Neuroscience(ANRO.US) With Buy Rating, Announces Target Price $35 - Moomoo
BofA initiates Alto Neuroscience stock coverage with buy rating By Investing.com - Investing.com Canada
BofA initiates Alto Neuroscience stock coverage with buy rating - Investing.com UK
Alto Neuroscience Presents Phase 2a Data for ALTO-207 in Major Depressive Disorder at SOBP Annual Meeting - BioSpace
Alto Neuroscience reports positive phase 2a depression trial - Investing.com
Alto Neuroscience reports positive phase 2a depression trial By Investing.com - Investing.com Canada
Alto Neuroscience, Immunovant and other big stocks moving lower in Thursday's pre-market session - MSN
Top Alto Neuroscience (ANRO) Competitors 2026 - MarketBeat
Alto Neuroscience (ANRO) price target increased by 15.20% to 36.72 - MSN
ANRO stock on investors’ radar after failed schizophrenia study results - MSN
Alto Neuroscience, Inc. (NYSE:ANRO) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Analysts Offer Insights on Healthcare Companies: Alto Neuroscience, Inc. (ANRO), Arcutis Biotherapeutics (ARQT) and Valneva (VALN) - The Globe and Mail
ANRO (Alto Neuroscience Inc.) Q4 2025 EPS misses forecasts, stock edges down 1.36 percent following its latest quarterly earnings release.Expert Momentum Signals - Xã Thanh Hà
Alto Neuroscience (NYSE:ANRO) Earns "Buy" Rating from Chardan Capital - MarketBeat
Alto Neuroscience (NYSE:ANRO) Reaches New 1-Year HighStill a Buy? - MarketBeat
Alto Neuro (ANRO) Stock Volume Deceleration (Surges) 2026-04-22Short Term Trading - Xã Châu Thành
Chardan Capital Maintains Alto Neuroscience(ANRO.US) With Buy Rating, Maintains Target Price $30 - Moomoo
Alto Neuroscience launches phase 2b trial for depression drug By Investing.com - Investing.com India
Alto Neuroscience (NYSE:ANRO) Shares Down 7.2%Here's Why - MarketBeat
Alto Neuroscience Starts Phase 2b Trial of ALTO-207 in Treatment-Resistant Depression - marketscreener.com
Alto Settles on Trials for Depression Drug - Baystreet.ca
Alto Neuroscience Initiates Phase 2b Trial of ALTO-207 in Treatment-Resistant Depression - BioSpace
Alto Neuroscience launches phase 2b trial for depression drug - Investing.com
[EFFECT] Alto Neuroscience, Inc. SEC Filing - Stock Titan
Four Major Data Readouts by 2026: Why Alto Neuroscience (ANRO) is on the Radar - AlphaStreet
ANRO Stock Price, Quote & Chart | ALTO NEUROSCIENCE INC (NYSE:ANRO) - ChartMill
Analysts’ Top Healthcare Picks: Boston Scientific (BSX), Alto Neuroscience, Inc. (ANRO) - The Globe and Mail
Alto Neuroscience (NYSE:ANRO) Hits New 52-Week HighHere's What Happened - MarketBeat
Alto Neuroscience (NYSE:ANRO) Trading 8.8% HigherHere's What Happened - MarketBeat
Wall Street Recap: Is Alto Neuroscience Inc benefiting from interest rate changes2026 Earnings Surprises & Fast Gaining Stock Strategy Reports - baoquankhu1.vn
Alto NeuroscienceProposed resale of up to 6 million shares of common stock by selling stockholdersSEC filing - marketscreener.com
Alto Neuroscience (NYSE: ANRO) registers 6M resale shares from private placement - Stock Titan
Top 1% Alto Neuroscience plummets on its shocking schizophrenia miss - MSN
What Do Analysts Think About the Biopharma Set on Transforming Psychiatry - Streetwise Reports
California Biotech Co. Advances Depression Drug Breakthrough - Streetwise Reports
Can Alto Neuro (ANRO) Stock Double in 2026 | Price at $21.99, Up 3.00%Reward Analysis - Xã Thanh Hà
Q1 Earnings Estimate for ANRO Issued By HC Wainwright - MarketBeat
Analysts Conflicted on These Healthcare Names: Merck & Company (MRK) and Alto Neuroscience, Inc. (ANRO) - The Globe and Mail
H.C. Wainwright reiterates Alto Neuroscience stock rating at buy By Investing.com - Investing.com Canada
Will Alto Neuro (ANRO) Stock Go Higher | Price at $21.63, Down 0.23%Fast Rising Picks - Cổng thông tin điện tử tỉnh Tây Ninh
Analysts Offer Insights on Healthcare Companies: Boston Scientific (BSX) and Alto Neuroscience, Inc. (ANRO) - The Globe and Mail
Alto Neuroscience, Immunovant And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Sahm
Crude Oil Rises Sharply; Acuity Shares Fall After Q2 Results - Sahm
Why Globalstar Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket - Sahm
Analysts Offer Insights on Healthcare Companies: Jasper Therapeutics (JSPR), Alto Neuroscience, Inc. (ANRO) and Viridian Therapeutics (VRDN) - The Globe and Mail
Chardan Capital Remains a Buy on Alto Neuroscience, Inc. (ANRO) - The Globe and Mail
Alto Neuroscience Inc Stock (ANRO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):